33,894 Shares in GeneDx Holdings Corp. $WGS Purchased by Lazard Asset Management LLC

Posted by Geri Gentry on Aug 3rd, 2026

Lazard Asset Management LLC acquired a new position in shares of GeneDx Holdings Corp. (NASDAQ:WGS – Free Report) in the 1st quarter, HoldingsChannel reports. The firm acquired 33,894 shares of the company’s stock, valued at approximately $2,177,000.

Other hedge funds have also made changes to their positions in the company. Westfield Capital Management Co. LP lifted its position in shares of GeneDx by 87.1% in the fourth quarter. Westfield Capital Management Co. LP now owns 1,018,261 shares of the company’s stock valued at $132,435,000 after acquiring an additional 474,167 shares in the last quarter. Franklin Resources Inc. boosted its stake in shares of GeneDx by 60.4% in the fourth quarter. Franklin Resources Inc. now owns 1,092,988 shares of the company’s stock worth $142,154,000 after acquiring an additional 411,607 shares during the last quarter. Invesco Ltd. increased its position in shares of GeneDx by 59.2% during the fourth quarter. Invesco Ltd. now owns 786,466 shares of the company’s stock worth $102,288,000 after purchasing an additional 292,394 shares in the last quarter. Amova Asset Management Americas Inc. increased its position in shares of GeneDx by 67.3% during the first quarter. Amova Asset Management Americas Inc. now owns 638,800 shares of the company’s stock worth $41,024,000 after purchasing an additional 257,075 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. raised its stake in GeneDx by 65.9% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 633,457 shares of the company’s stock valued at $40,681,000 after purchasing an additional 251,732 shares during the last quarter. Institutional investors and hedge funds own 61.72% of the company’s stock.

GeneDx News Summary

Here are the key news stories impacting GeneDx this week:

Positive Sentiment: Zacks Research upgraded GeneDx from “strong sell” to “hold,” indicating a less bearish view of the shares, although the rating does not represent a bullish recommendation. Zacks.com
Neutral Sentiment: The numerous announcements largely repeat the same legal notice: investors who purchased GeneDx shares between April 16, 2025, and May 4, 2026, may apply to lead the lawsuit by August 3. The notices are investor-solicitation releases rather than new operational or financial developments. Rosen Law Firm deadline notice
Negative Sentiment: Several firms, including Hagens Berman, Rosen Law Firm, Robbins Geller, Bragar Eagel & Squire, and others, confirmed or promoted a securities-fraud class action against GeneDx. The lawsuit alleges violations of federal securities laws and claims that the company made misleading statements regarding acquisition performance and related business prospects. Hagens Berman class action notice
Negative Sentiment: One notice links the allegations to an asserted 49% stock decline, citing a reported $51 million acquisition expectation followed by a $31.2 million write-off within roughly 12 months. These allegations have not been proven in court, but the litigation creates potential legal costs, reputational risk, and uncertainty for shareholders. Kahn Swick and Foti class action notice

Insider Buying and Selling

In other news, CFO Kevin Feeley sold 3,729 shares of GeneDx stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $60.77, for a total transaction of $226,611.33. Following the transaction, the chief financial officer owned 39,954 shares in the company, valued at $2,428,004.58. The trade was a 8.54% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Casdin Capital, Llc purchased 50,000 shares of the stock in a transaction dated Friday, June 5th. The shares were purchased at an average cost of $52.86 per share, for a total transaction of $2,643,000.00. Following the transaction, the director owned 3,707,164 shares in the company, valued at approximately $195,960,689.04. The trade was a 1.37% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders acquired 2,256,420 shares of company stock valued at $93,144,340 and sold 19,135 shares valued at $1,128,499. 25.17% of the stock is currently owned by insiders.

GeneDx Price Performance

NASDAQ:WGS opened at $65.11 on Monday. GeneDx Holdings Corp. has a one year low of $32.21 and a one year high of $170.87. The stock has a market cap of $1.93 billion, a PE ratio of -24.29 and a beta of 1.92. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.95 and a current ratio of 3.09. The stock has a 50 day moving average price of $60.67 and a 200 day moving average price of $69.59.

GeneDx (NASDAQ:WGS – Get Free Report) last released its quarterly earnings data on Monday, May 4th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.22). The company had revenue of $102.25 million for the quarter, compared to analyst estimates of $112.46 million. GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.During the same period last year, the firm posted ($0.23) EPS. Equities research analysts expect that GeneDx Holdings Corp. will post -1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

WGS has been the topic of a number of research reports. Guggenheim restated a “buy” rating and issued a $74.00 price objective (up from $70.00) on shares of GeneDx in a report on Monday, June 29th. Weiss Ratings lowered shares of GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 1st. Piper Sandler reiterated an “overweight” rating and issued a $63.00 target price (up from $50.00) on shares of GeneDx in a research report on Tuesday, June 23rd. BTIG Research decreased their price target on shares of GeneDx from $170.00 to $90.00 and set a “buy” rating on the stock in a research note on Tuesday, May 5th. Finally, Wells Fargo & Company restated an “overweight” rating and set a $75.00 price target (down from $155.00) on shares of GeneDx in a research report on Tuesday, May 5th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, GeneDx presently has an average rating of “Moderate Buy” and an average target price of $87.43.

View Our Latest Research Report on WGS

GeneDx Profile

(Free Report)

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.